Genomic Health, Inc.  

(Public, NASDAQ:GHDX)   Watch this stock  
Find more results for GHDX
28.15
+0.33 (1.19%)
After Hours: 28.15 0.00 (0.00%)
Jul 26, 5:18PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 27.61 - 28.98
52 week 20.05 - 35.79
Open 27.61
Vol / Avg. 69,377.00/160,934.00
Mkt cap 916.85M
P/E     -
Div/yield     -
EPS -0.93
Shares 33.02M
Beta 0.48
Inst. own 94%
Aug 2, 2016
Q2 2016 Genomic Health Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 10, 2016
Genomic Health Inc Annual Shareholders Meeting (Estimated)
Jun 9, 2016
Genomic Health Inc Annual Shareholders Meeting
Jun 7, 2016
Genomic Health Inc at Jefferies Healthcare Conference
May 10, 2016
Genomic Health Inc at Bank of America Merrill Lynch Health Care Conference
May 4, 2016
Q1 2016 Genomic Health Inc Earnings Call
May 4, 2016
Q1 2016 Genomic Health Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -7.85% -11.59%
Operating margin -10.89% -11.84%
EBITD margin - -9.38%
Return on average assets -14.06% -17.98%
Return on average equity -18.40% -23.37%
Employees 802 -
CDP Score - -

Address

301 Penobscot Dr
REDWOOD CITY, CA 94063-4700
United States - Map
+1-650-5569300 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Genomic Health, Inc. is a healthcare company, which provides genomic-based diagnostic tests for the treatment of early stage cancer. The Company offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS) and a Genomic Prostate Score for prostate cancer. Its Oncotype DX tests utilizes quantitative genomic analysis known as reverse transcription polymerase chain reaction, in standard tumor pathology specimens to provide tumor-specific information, or the oncotype of a tumor. It offers its services and products, including Oncotype DX Breast Cancer Test, Oncotype DX Colon Cancer Test and Oncotype DX Prostate Cancer Test through its Oncotype IQ Genomic Intelligence Platform.

Officers and directors

Kimberly J. Popovits Chairman of the Board, President, Chief Executive Officer
Age: 56
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Gordon Bradley Cole Chief Financial Officer, Chief Operating Officer, Secretary
Age: 60
Bio & Compensation  - Reuters
Steven Shak M.D. Chief Scientific Officer
Age: 64
Bio & Compensation  - Reuters
Julian C. Baker Lead Independent Director
Age: 50
Bio & Compensation  - Reuters
Geoffrey M. Parker Director
Age: 51
Bio & Compensation  - Reuters
Felix J. Baker Ph.D. Independent Director
Age: 47
Bio & Compensation  - Reuters
Fred E. Cohen Ph.D., M.D. Independent Director
Age: 59
Bio & Compensation  - Reuters
Henry J. Fuchs M.D.,Ph.D. Independent Director
Age: 58
Bio & Compensation  - Reuters